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Abstract Fas(Apo-l/CD95), a receptor belonging to the tumor 
necrosis factor receptor family, induces apoptosis when triggered 
by Fas ligand. Upon its activation, the cytoplasmic domain of 
Fas binds several proteins which transmit the death signal. We 
used the yeast two-hybrid screen to isolate Fas-associated 
proteins. Here we report that the ubiquitin-conjugating enzyme 
UBC9 binds to Fas at the interface between the death domain 
and the membrane-proximal region of Fas. This interaction is 
also seen in vivo. UBC9 transiently expressed in HeLa cells 
bound to the co-expressed cytoplasmic segment of Fas. FAF1, a 
Fas-associated protein that potentiates apoptosis (Chu et al. 
(1996) Proc. Natl. Acad. Sci. USA 92,11894-11898), was found 
to contain sequences similar to ubiquitin. These results suggest 
that proteins related to the ubiquitination pathway may modulate 
the Fas signaling pathway. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Apoptosis, or programmed cell death, is essential for the 
homeostasis of multicellular organisms [1]. Apoptosis is most 
efficiently induced by Fas (Apo-l /CD95) [2,3]. Fas is a trans-
membrane receptor of the T N F family of receptor proteins 
which are characterized by a conserved cysteine-rich extracel-
lular domain [4]. U p o n binding of the natural ligand (FasL) 
or crosslinking with antibodies, cells expressing Fas undergo 
rapid apoptosis [5,6]. 
Despite its importance, the mechanisms underlying Fas-
mediated apoptosis still remain unclear. Members of the 
growing family of cysteine proteases specific for aspartic 
acid (Caspases) appear to be implicated in the execution phase 
of cell death [7]. Signaling of apoptosis immediately following 
activation of Fas leads to activation of caspases via the Fas-
interacting protein F A D D / M O R T 1 [8,9] and subsequent acti-
vation of F L I C E / M A C H proteases [8,10]. 
In order to define additional candidate proteins implicated 
in Fas signaling, we performed a two-hybrid screen using the 
intracellular domain of Fas as bait. We screened a mouse 
embryo library and obtained several clones coding for two 
distinct proteins. One of these represents UBC9, a member 
of the E2 family of ubiquitin conjugating enzymes. 
Ubiquitination of proteins plays a role as a signal for the 
intracellular degradation of proteins by proteasomes [11,12]. 
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Briefly, in the ubiquitination reaction, ubiquitin is first acti-
vated by an activation enzyme, E l . It is then transferred to a 
cysteine residue of a ubiquitin-conjugating enzyme (E2 en-
zyme). The E2 enzyme, either alone or together with a ubiq-
uitin-protein ligase, E3, catalyzes the transfer of ubiquitin to a 
lysine residue of the target protein which is thereby marked 
for degradation by proteasomes. In yeast, UBC9 represents 
one out of at least ten different E2 enzymes. It mediates de-
struction of S- and M-phase cyclins and is essential for via-
bility [13]. The mouse and human UBC9 homologues were 
recently cloned as proteins interacting with the Rad51 recom-
bination protein [14]. 
We now show that UBC9 is present in the cytosol and 
nucleus of transfected cell lines and that it associates with 
the intracellular domain of the Fas receptor. 
2. Material and methods 
2.1. Cloning of Fas cytosolic domain fusion proteins 
A DNA fragment coding for the cytosolic domain of murine Fas 
(Ser183—Glu306) was excised Xbal-Pstl from pKS(+) containing the 
entire murine Fas [15], and subcloned into PKS(+) (Stratagene). 
The cytosolic fragment of Fas in this vector from Notl (5') (filled in 
with Klenow polymerase) to Sail (3') was cloned into the BamHI 
(filled in) and Sail sites of the vector PGBT9 (Clontech) thus creating 
a fusion protein of the Gal4-DNA binding domain and Fas (pGBT-
Fas). 
A series of fragments and deletion mutations of the Fas cytosolic 
domain were produced by PCR (using oligonucleotides that contain 
an added Smal site at the 5' end or an added BamHI site at the 3' end 
of the insert) and cloned in frame into the Smal and BamHI sites of 
the Gal4-DNA binding domain vector PGBT9 (Clontech). The fol-
lowing fragments were amplified: Arg166-Glu306, Arg16C-Asp288, 
Leu200-Leu289, Ile207-Leu289, Leu289-Glu306. The Fas cytosolic do-
main lpfg (I225N) (Arg166-Glu306) mutation was created by PCR us-
ing mutated oligonucleotides and equally cloned into pGBT9. A fur-
ther truncated version of Fas was constructed by digestion with Xhol 
(Ala220) and relegation into the Sail site of the vector (Arg166-Ala220). 
2.2. Two-hybrid screen 
A mouse embryo cDNA library cloned into the Notl-site of the 
vector pVP16 [16] which codes for fusion proteins of the viral tran-
scription activation domain VP16 was obtained from S. Hollenberg 
(Vollum Institute, Portland, Oregon). Yeast strain Y153 [17] was 
transformed with pGBT-Fas and the library plasmids and analyzed 
for interaction of the proteins [18]. Mating tests [19] were performed 
using yeast Y187 (MATa) and Y190 (MATa) transformed with the 
bait and library plasmids, respectively. 
2.3. Transfection of mammalian cells 
For expression in mammalian cells, the cDNAs corresponding to 
mouse UBC9 (R. Bernards, Amsterdam, Netherlands) or fragments 
thereof were cloned into pCR3 (Invitrogen) and tagged with either a 
flag or a myc epitope at the N-terminus [20]. The complete cytosolic 
domain of Fas (Arg166-Glu306) was tagged with a flag epitope at its 
N-terminus and cloned into pCR3 (Invitrogen). The FADD cDNA in 
the pcDNA3 vector (Invitrogen) was obtained from J.C. Martinou, 
Glaxo, Geneva. 
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Plasmids were transiently transfected into HeLa or 293T cells (293 
cells, ATCC CRL 1573, expressing the SV40-T antigen, obtained from 
M. Peter, Heidelberg) using the calcium-phosphate precipita-
tion method [21]. Protein expression was controlled by separat-
ing cell extracts on a polyacrylamide gel and subsequent immunoblot-
ting. 
2.4. Immunofluorescence staining 
Transfected HeLa cells were grown on sterile coverslips prior to 
immunofluorescence. Cells were then washed in PBS, fixed in 4% 
formaldehyde and permeabilized with 0.1% saponin in PBS. Trans-
fected proteins were stained with monoclonal antibody to the flag 
epitope (M2, Kodak). After extensive washing, an antibody against 
mouse immunoglobulins conjugated to FITC (Dianova, Hamburg, 
Germany) was added. Slides were mounted using FluorSave Reagent 
(Calbiochem) and analyzed using a Zeiss Axiophot microscope. 
2.5. Immunoprecipitation 
293T cells were transfected with flag-tagged Fas cytosolic domain 
and myc-tagged UBC9 in a 25 cm2 plate. Cells were lysed in 1 ml lysis 
buffer [22] and precipitated with a monoclonal antibody to the flag tag 
coupled to agarose (M2, Kodak). Co-precipitation of myc-tagged 
UBC9 was analyzed by Western blot using the monoclonal anti-myc 
antibody 9E10 (gift from R. Iggo, ISREC, Epalinges). Anti-FADD 
monoclonal antibodies were purchased from Transduction Laborato-
ries, Lexington. 
3. Results 
3.1. Identification of UBC9 as a protein binding partner of Fas 
We used the yeast two-hybrid system to screen for proteins 
that interact with the cytosolic domain of the Fas/Apo-1 re-
ceptor. As bait we fused the fragment of Fas from Ser183 to 
Glu306 to the Gal4 DNA binding domain. This plasmid was 
transformed into yeast strain Y153 along with a library of 
mouse embryo cDNA fused to the transcription activation 
domain VP16 [22]. Twenty-seven positive clones were ob-
tained from 5 x 106 clones screened. Sequencing of the inserts 
revealed that four inserts corresponded to the mouse homo-
logue of the S. cerevisiae ubiquitin-conjugating enzyme UBC9 
[13,14]. Three of the clones were identical. All of the clones 
lacked the 2 C-terminal amino acids of full-length UBC9, and 
one clone additionally lacked 6 amino acids at the N-termi-
nus. The full-length mouse UBC9 cDNA (obtained from R. 
Bernards) was subsequently cloned into the vectors for the 
two-hybrid system to confirm the results. UBC9 interacted 
specifically with Fas (Fig. 1), but not with the proteins lamin 
A, LDL receptor, or poly Ig receptor (not shown) used as 
control. 
Fig. 1. Interaction of UBC9 and Fas in the yeast two-hybrid system. TM, transmembrane segment of Fas; DD, death domain; ID, inhibitory 
domain, binds to FAP-1. Several deletion mutations of the cytosolic domain of Fas were cloned as fusion proteins with the DNA binding do-
main of Gal4. Interaction of these with the VP16 fusion protein of UBC9 was tested in the two-hybrid system. Growth on histidine-lacking me-
dia and p-galactosidase activity is indicated. +++: strong reaction (large colonies, dark blue 213color), +: weak interaction (small colonies, 
faint blue color). 
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3.2. Localization of the Fas-UBC9 interaction site 
In order to characterize the interactions of UBC9 and Fas 
more precisely, we constructed several truncated versions of 
the Fas cytosolic domain (Fig. 1). Both the complete UBC9 
protein and the fragments obtained in the two-hybrid screen 
interacted very strongly with the entire cytosolic domain of 
Fas (Arg166-Glu306) and with the fragments which lacked ei-
ther 17 amino acids adjacent to the membrane-interacting 
segment (Ser183-Glu306) or the C-terminal 18 amino acids 
(Arg166-Asp288) (Fig. 1). Neither of the UBC9 proteins inter-
acted with the fragment of Fas corresponding to the death 
domain (Ile207-Asp288) alone or with the C-terminal 18 amino 
acids (Leu289-Glu306) known to interact with FAP-1 [23]. In 
contrast, weak but detectable interaction was found with frag-
Fig. 3. Immunofluorescence of UBC9. HeLa cells were transfected 
with UBC9 tagged with a flag epitope at its N-terminus, fixed on a 
coverslip, and stained with anti-flag antibody (lower panel). The 
corresponding phase-contrast image is shown in the upper panel. 
The bar corresponds to a distance of 15 um. 
Fig. 2. Interaction of UBC9 and Fas in mammalian cells. (A) 293T 
cells were transfected with, from left to right, (a) flag-tagged Fas cy-
tosolic domain (10 ug plasmid), (b) myc-tagged UBC9 (2 ug), (c) 
flag-tagged Fas cytosolic domain (2 ug plasmid) and myc-tagged 
UBC9 (8 ug), and (d) flag-tagged Fas cytosolic domain (8 ug plas-
mid) and myc-tagged UBC9 (2 ug). Cells were lysed and postnu-
clear supernatant analyzed by Western blot (top two panels) using 
Fas-detecting anti-flag and UBC9-detecting anti-myc antibodies, re-
spectively. In the third panel, experiments are shown where Fas was 
first precipitated (IP) from lysates of transfected cells with anti-flag 
antibodies bound to agarose. Precipitates were subsequently ana-
lyzed by Western blot for the co-precipitation of myc-tagged UBC9. 
(B) Control experiment: interaction of FADD and Fas in mammali-
an cells. 293T cells were either transfected with FADD cDNA alone 
(a) or co-transfected with FADD and flag-tagged Fas cytosolic do-
main (b). The left panel shows a Western blot of lysates of trans-
fected cells using an anti-FADD antibody. In the right panel (IP), 
Fas, when present, was first precipitated (IP) with anti-flag antibod-
ies bound to agarose. Precipitates were subsequently analyzed by 
Western blot for the co-precipitation of FADD. 
ments in which the death domain was flanked by additional 
15 amino acids at its N-terminus (Leu200-Leu289) or when the 
fragment contained the complete membrane proximal part, 
but only 7 residues of the death domain (Arg166-Ala220). In 
addition, UBC9 interacted only weakly with the cytosolic do-
main of Fas which contained a mutation in the death domain 
corresponding to the lprcg [24] mutation in mice which renders 
Fas inactive [25]. From these experiments, we conclude that 
efficient binding of UBC9 to the cytosolic domain of Fas 
requires both a functional death domain and part of the mem-
brane proximal segment. 
3.3. Interaction of UBC9 and Fas in vivo 
To confirm that interaction of Fas with UBC9 occurs in 
vivo, 293T human embryo kidney cells were co-transfected 
with a plasmid coding for the cytosolic domain of Fas tagged 
with a flag epitope and a plasmid coding for mouse UBC9 
tagged with a myc epitope. Cells were lysed and subjected to 
immunoprecipitation using an anti-flag epitope antibody. The 
immunoprecipitates were analyzed by Western blot using an 
antibody against the myc epitope. UBC9 was only precipi-
tated if it was coexpressed with Fas (Fig. 2A). If the two 
proteins were expressed separately and the cell lysates were 
mixed before immunoprecipitation, no binding was observed 
(data not shown) indicating that Fas and UBC9 interaction is 
weak. As expected, the transiently expressed cytoplasmic seg-
ment of Fas strongly interacted with FADD/Mortl (Fig. 2B). 
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Fig. 4. Sequence homology of FAFl with proteins involved in the ubiquitin pathway. For establishing the homology, the generalized profile 
method was used. Alignment of the two regions of FAFl homologous to ubiquitin (ubiq) is shown. The most conserved amino acids in ubiqui-
tin-like proteins are listed below the alignment. Black-boxed residues correspond to identical amino acids in at least two of the three sequences 
shown, shaded amino acids represent conserved residues. X = homology with C. elegans ORF C281.1; UX = homology with proteins involved 
in ubiquitination pathway. Accession numbers: mouse FAFl: gb: U39643, human ubiquitin: P02248 (76 aa), C28gl.l: gb: U41026. 
3.4. UBC9 is present in the cytosol and the nucleus 
Yeast UBC9 has been reported to be active in the nucleus 
of yeast [13]. Since our experiments indicated that UBC9 was 
interacting with the cytoplasmic domain of Fas, it was impor-
tant to investigate whether UBC9 was also present in the 
cytoplasm of mammalian cells. The flag-tagged UBC9 expres-
sion construct was transiently expressed in HeLa cells and 
localization of the protein was analyzed by immunofluores-
cence. As shown in Fig. 3, UBC9 was expressed in the cytosol 
of transfected cells. A considerable portion was also found in 
the nucleus suggesting that the protein shuttles between the 
two cellular compartments. The same result was obtained with 
a myc-tagged version of UBC9 in COS cells (data not shown). 
This localization is consistent with the binding of UBC9 to the 
cytosolic domain of Fas. 
4. Discussion 
Using the two-hybrid screen, we have identified the ubiq-
uitin-conjugating enzyme UBC9 as a Fas-interacting protein, 
increasing to date the number of proteins known to associate 
with the cytoplasmic segment of Fas to five. This finding is in 
agreement with recently published data by Wright et al. [26], 
who reported that Fas interacts with UBC-FAP (identical to 
UBC9). In addition to UBC9, two death domain containing 
proteins, i.e. FADD/MORT1 [8,9] and RIP [27], specifically 
interact with the death domain of Fas. Whereas the role of 
FADD/MORT1 is to physically link the FLICE/MACH pro-
teases to Fas and thus initiate apoptosis [10,28], RIP's func-
tion in Fas-mediated cell death is less clear as it preferentially 
associates with TNFR1 via the death domain protein 
TRADD [29]. Fas also interacts with two proteins that lack 
death domains, i.e. FAFl and FAP-1. FAFl, if overexpressed 
in mammalian cells, potentiates apoptosis [30], in contrast to 
the phosphatase FAP-1 which has been reported to act as 
inhibitor of cell death [31]. FAP-1 binds to the carboxyl-ter-
minal 15 amino acids of Fas, a sequence known to represent a 
negative regulator of Fas-induced apoptosis [32]. The FAFl 
binding region in Fas has not been mapped precisely. Similar 
to UBC9, FAFl is unable to interact with the Fas lpf& mu-
tation and no homology with any known sequence in the data 
banks was found. Using a generalized profile method [33], 
however, sequence similarity with several sequence motifs 
present in proteins of the ubiquitination pathway became ap-
parent (Fig. 4). First, one repeated motif homologous to ubiq-
uitin itself is present in the N-terminus of FAFl. Second, the 
C-terminus comprises a UX sequence motif present in pro-
teins implicated in ubiquitin conjugation [34]. Finally, the 
middle region of FAFl shows sequence similarity with a motif 
(X) found in the C. elegans ORF C28G1.1 where this (X) 
motif is found adjacent to a sequence homologous to UBC9. 
The physiological relevance of the association of Fas intra-
cellular domain with two proteins apparently implicated in the 
ubiquitination pathway remains to be elucidated. When FAFl 
is overexpressed, the percentage of apoptotic cells increases 
through Fas signaling, suggesting that it is a positive regulator 
of apoptosis. We have observed no effect on overexpression of 
UBC9 in mammalian cells, probably reflecting the high en-
dogenous levels already present in most mammalian systems 
[14]. There are several possible explanations for the UBC9/Fas 
interaction. First, UBC9 may be directly involved in ubiqui-
tin-dependent degradation of Fas by proteasomes. Fas signal-
ing leads to rapid apoptosis and one mechanism to control 
this potentially dangerous death pathway could be to limit the 
half-life of the receptor. Although nothing is known on the 
stability of Fas and possible ubiquitination, the related 
TNFR1 appears to be short-lived [35]. Interestingly, TNFR 
was shown to be ubiquitinated [36] and to bind a protein 
related to a proteasome subunit upstream of the death do-
main [35,37]. Second, Fas may target UBC9 to membrane 
sites where ubiquitination of neighboring proteins may trigger 
events required for apoptosis. Proteasome proteolytic activity 
is required for certain apoptotic pathways in neurons and 
thymocytes [38,39]. However, modification of proteins by 
ubiquitin can have consequences other than direct targeting 
to the 26S proteasome. Ubiquitination may act as a signal for 
receptor endocytosis to lysosomes as recently reported for a 
yeast plasma membrane receptor [40]. Moreover, the biosyn-
thesis or activity of several receptor proteins has been shown 
to be regulated by ubiquitination, as in the case of the cystic 
fibrosis transmembrane regulator, the T-cell receptor, the 
platelet-derived growth factor receptor and an IKBOC protein 
kinase [41]. Understanding the role of the ubiquitination path-
way related proteins FAFl and UBC9 in Fas signaling will 
certainly lead to a better understanding of how apoptotic 
signals are modulated. 
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